Antibody Sequencing Service Recombinant Antibody Articles & Analysis: Older
13 news found
Introduction We recently sat down with one of our valued customers, Dr Alexis Rossignol (Clean Cells), to discuss his experience with VIPS PRO, our cutting-edge technology designed to streamline and enhance the early stages of cell line development. This interview provides insight into Clean Cells’ quest to automate and increase single-cell seeding while having undisputable proof ...
Known for its competence, responsibility, and innovative capability in chemical supply, Alfa Chemistry recently unveiled its new role as a CDMO service provider for pharmaceutical companies worldwide. Contract Development and Manufacturing Organization, abbreviated as CDMO, is a preferential way for a majority of pharmaceutical companies to outsource ongoing drug development and drug ...
Actym Therapeutics, a privately held biotechnology company developing STACT, a novel therapeutic platform that delivers immunomodulatory payloads to solid tumors after IV dosing, announced today the significant expansion of its senior leadership team. Dr. Julie Cherrington joins as BOD Chair, James Stutz joins as Chief Business Officer, and Dr. Omkar Joshi joins as Vice President, Technical ...
As a global leading supplier of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently launches a series of NiV recombinant antigen and antibody pairs. All of these new products are produced using standardized production processes to ensure the highest quality. Tests developed using these reagents can assist researchers in routine diagnostics and NiV ...
CD BioGlyco, a biotechnology company that provides a full range of glycobiology-related products, analysis, custom synthesis, and design to help advance glycobiology research, recently released a glyco-engineered mammalian cell expression system to help scientists with their research. New biotherapeutic glycoproteins, such as recombinant monoclonal antibodies (mAbs), have been widely used to ...
Immune Biosolutions Inc., a clinical-stage company, is pleased to announce that its leading biological drug candidate maintains a potent activity in neutralization assays. Recent results have confirmed that this drug, IBIO123, is capable of neutralizing SARS-CoV-2 (COVID-19) and all its current variants of concern (VOCs) that have emerged throughout the pandemic, including the latest Omicron ...
BIO DIGITAL 2021 – New and emerging biopharma companies working on early development can now leverage a better lab to clinic drug development solution designed to accelerate the journey from DNA to drug product. The enhanced Quick to Clinic solution from Thermo Fisher Scientific may help biopharma companies reach Phase I/First-In-Human trials and file for Investigational New Drug (IND) ...
INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today reported financial results for the quarter ended December 31, 2020. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time today to discuss ...
Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, today announced the expansion of its leadership team with the appointment of a Chief Scientific Officer and two additional Board members. Virometix filled a vacancy in its management team with the ...
Grifols (MCE: GRF, MCE: GRF.P,NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced it has entered into a transaction to acquire the remaining equity of Alkahest, Inc. in exchange for a total price of $146 million, on a debt-free basis. No additional financing will be required. The closing of the ...
Abologix has obtained impressive data with its anti-JAM-C recombinant monoclonal antibody rH225 in an animal Mantle Cell Lymphoma (MCL) NOD/SCID mouse model. In this study the efficacy of rH225 was tested by assessing: the delayed mortality upon Jeko-1 MCL cell injection and the reduction of Jeko-1 cells burden in the blood, spleen, lymph nodes, bone marrow and liver rH225 delayed ...
ByAbologix
Immune Biosolutions Inc. (IBio), a JLABS @ Toronto resident company, today announced a research collaboration and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement, facilitated by Johnson & Johnson Innovation LLC, will focus initially on the discovery and development of therapeutic antibodies in oncology. The ...
CQDM is pleased to announce the funding of a new $1.1 million research project in conjunction with financial contributions from lead industrial partner, Immune Biosolutions, and co-funding from: Cancer Research Society, Mitacs, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke and TransferTech. The funds will be used by the Université de Sherbrooke’s Professors ...